The Spice Sage and Its Active Ingredient Rosmarinic Acid Protect PC12 Cells from Amyloid-β Peptide-Induced Neurotoxicity

Traditional use and clinical reports suggest that the culinary herb sage (Salvia officinalis) may be effective for patients with mild to moderate Alzheimer's disease (AD). In this study, we evaluated the effect of a standardized extract from the leaves of S. officinalis (SOE) and its active ingredient rosmarinic acid on Alzheimer amyloid-β peptide (Aβ)-induced toxicity in cultured rat pheochromocytoma (PC12) cells. Incubation of PC12 cells with Aβ (fragment 1–42) for 24 h caused cell death, and this effect was reduced by SOE and its active ingredient, rosmarinic acid. Rosmarinic acid reduced a number of events induced by Aβ. These include reactive oxygen species formation, lipid peroxidation, DNA fragmentation, caspase-3 activation, and tau protein hyperphosphorylation. Moreover, rosmarinic acid inhibited phosphorylated p38 mitogen-activated protein kinase but not glycogen synthase kinase 3β activation. These data show the neuroprotective effect of sage against Aβ-induced toxicity, which could validate the traditional use of this spice in the treatment of AD. Rosmarinic acid could contribute, at least in part, for sage-induced neuroprotective effect.

[1]  A. D. Cash,et al.  Therapeutic potential in Alzheimer disease. , 2002, Current medicinal chemistry.

[2]  R. Carnuccio,et al.  The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. , 2006, Journal of molecular medicine.

[3]  L. Gao,et al.  Antiapoptotic and antioxidant effects of rosmarinic acid in astrocytes. , 2005, Die Pharmazie.

[4]  R E Burke,et al.  Apoptosis in neurodegenerative disorders. , 1997, Current opinion in neurology.

[5]  J. Ávila,et al.  Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. , 1999, FEBS letters.

[6]  F. Galvano,et al.  Effects of rosmarinic acid against aflatoxin B1 and ochratoxin‐A‐induced cell damage in a human hepatoma cell line (Hep G2) , 2004, Journal of applied toxicology : JAT.

[7]  I. Fabian,et al.  The p38 pathway partially mediates caspase-3 activation induced by reactive oxygen species in Fanconi anemia C cells. , 2004, Biochemical pharmacology.

[8]  Angelo A. Izzo,et al.  The marijuana component cannabidiol inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue in PC12 cells , 2006, Journal of Molecular Medicine.

[9]  T. Gómez-Isla,et al.  Expression of stress‐activated kinases c‐Jun N‐terminal kinase (SAPK/JNK‐P) and p38 kinase (p38‐P), and tau hyperphosphorylation in neurites surrounding βA plaques in APP Tg2576 mice , 2004, Neuropathology and applied neurobiology.

[10]  N. Perry,et al.  Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders , 2003, Phytotherapy research : PTR.

[11]  B. Zhivotovsky,et al.  A comparative study of apoptosis and necrosis in HepG2 cells: oxidant-induced caspase inactivation leads to necrosis. , 1999, Biochemical and biophysical research communications.

[12]  W. Ma,et al.  Amyloid β peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures , 2002, Neuroscience.

[13]  M. Simmonds,et al.  Rosmarinic acid. , 2003, Phytochemistry.

[14]  E. Perry,et al.  EUROPEAN HERBS WITH CHOLINERGIC ACTIVITIES: POTENTIAL IN DEMENTIA THERAPY , 1996 .

[15]  G. Wilcock,et al.  Evidence-based pharmacotherapy of Alzheimer's disease. , 2004, The international journal of neuropsychopharmacology.

[16]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[17]  Agneta Nordberg,et al.  PET imaging of amyloid in Alzheimer's disease , 2004, The Lancet Neurology.

[18]  T. Kubo,et al.  In vivo conversion of racemized β‐amyloid ([D‐Ser26]Aβ1–40) to truncated and toxic fragments ([D‐Ser26]Aβ25–35/40) and fragment presence in the brains of Alzheimer's patients , 2002 .

[19]  R. Bullock Future directions in the treatment of Alzheimer’s disease , 2004, Expert opinion on investigational drugs.

[20]  T. Yoshikawa,et al.  Absorption, metabolism, degradation and urinary excretion of rosmarinic acid after intake of Perilla frutescens extract in humans , 2005, European journal of nutrition.

[21]  Mohammad Reza Mohammadi,et al.  Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo‐controlled trial , 2003, Journal of clinical pharmacy and therapeutics.

[22]  Kenjiro Ono,et al.  Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro , 2004, Journal of neuroscience research.

[23]  Y. Yun,et al.  Rosmarinic Acid Induces p56lck-Dependent Apoptosis in Jurkat and Peripheral T Cells via Mitochondrial Pathway Independent from Fas/Fas Ligand Interaction 1 , 2004, The Journal of Immunology.

[24]  Andrea Caricasole,et al.  The Wnt pathway, cell-cycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer's disease? , 2003, Trends in pharmacological sciences.

[25]  Mohammad Reza Mohammadi,et al.  Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomised, placebo controlled trial , 2003, Journal of neurology, neurosurgery, and psychiatry.

[26]  A. Cuadrado,et al.  Effect of the Alzheimer amyloid fragment Aβ(25–35) on Akt/PKB kinase and survival of PC12 cells , 2001, Journal of neurochemistry.

[27]  I. Grundke‐Iqbal,et al.  Tau pathology in Alzheimer disease and other tauopathies. , 2005, Biochimica et biophysica acta.

[28]  H. Jung,et al.  Protective effect of diallyl disulfide on oxidative stress-injured neuronally differentiated PC12 cells. , 2005, Brain research. Molecular brain research.

[29]  J. Ávila,et al.  Lithium protects cultured neurons against β‐amyloid‐induced neurodegeneration , 1999 .

[30]  D. Butterfield,et al.  Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death , 2002, Neurobiology of Aging.

[31]  G. T. Liu,et al.  Protective action of seven natural phenolic compounds against peroxidative damage to biomembranes. , 1992, Biochemical pharmacology.

[32]  Jeffrey A. Johnson,et al.  Genetic Programming by the Proteolytic Fragments of the Amyloid Precursor Protein: Somewhere Between Confusion and Clarity , 2003, Reviews in the neurosciences.

[33]  E. Perry,et al.  Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial , 2003, Pharmacology Biochemistry and Behavior.

[34]  John Q Trojanowski,et al.  Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs , 2004, Nature Medicine.

[35]  E. Perry,et al.  Medicinal Plants and Alzheimer's Disease: from Ethnobotany to Phytotherapy ** , 1999, The Journal of pharmacy and pharmacology.

[36]  P. Doraiswamy Non-cholinergic strategies for treating and preventing Alzheimer's disease. , 2002, CNS drugs.

[37]  N. Holbrook,et al.  The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. , 1998, The Biochemical journal.

[38]  N. Thornberry,et al.  Caspases: killer proteases. , 1997, Trends in biochemical sciences.

[39]  J. Hohmann,et al.  Protective Effects of the Aerial Parts of Salvia officinalis, Melissa officinalis and Lavandula angustifolia and their Constituents against Enzyme-Dependent and Enzyme-Independent Lipid Peroxidation , 1999, Planta medica.

[40]  D. Baričevič,et al.  Topical anti-inflammatory activity of Salvia officinalis L. leaves: the relevance of ursolic acid. , 2001, Journal of ethnopharmacology.

[41]  P. Adlard,et al.  The cause of neuronal degeneration in Alzheimer's disease , 2000, Progress in Neurobiology.

[42]  V. Šimánek,et al.  Chemoprotective effect of plant phenolics against anthracycline‐induced toxicity on rat cardiomyocytes Part II. caffeic, chlorogenic and rosmarinic acids , 2004, Phytotherapy research : PTR.

[43]  M. Citron Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge. , 2004, Trends in pharmacological sciences.

[44]  T. Kubo,et al.  In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients. , 2002, Journal of neuroscience research.